Filing Overview
TriSalus Life Sciences, Inc. filed a Form 8-K dated May 15, 2024 under Item 2.02 to announce a business update and financial results for the quarter ended March 31, 2024. The filing furnishes, but does not include in the provided text, the related press release as Exhibit 99.1.
Financial Results and Key Metrics
The filing text does not provide clear values for revenue, net income or loss, cash flow, margins, debt, liquidity, operating expenses, or other financial metrics. These details appear to be contained in the furnished Exhibit 99.1 press release, which was not included in the source text.
Changes Versus Prior Period
The filing text does not provide quantitative or qualitative comparisons with the prior comparable period.
Outlook, Risks, and Other Matters
- The filing announces a business update, but provides no specific guidance, outlook, management commentary, contingencies, or risk disclosures in the supplied text.
- Exhibit 99.1 is furnished and is not deemed filed for purposes of Section 18 of the Exchange Act or Sections 11 and 12(a)(2) of the Securities Act, except as otherwise expressly provided in a subsequent filing.
- The company is an emerging growth company.
- The company’s common stock trades under the symbol TLSI and its warrants under TLSIW on the Nasdaq Global Market.
Investor Verification Items
- Obtain and review Exhibit 99.1 for the quarter’s revenue, profitability, cash flow, cash balance, debt, and liquidity figures.
- Verify any year-over-year or sequential changes and management’s stated operating drivers.
- Review the press release for guidance, financing needs, liquidity risks, contingencies, and unusual or nonrecurring items.
- Confirm whether the reported results are prepared under GAAP and reconcile any non-GAAP measures to the comparable GAAP measures.